At AAIC 2026, CervoMed Unveils Phase 2b Data Supporting Neflamapimod's Benefit in Pure DLB and the Planned Phase 3 Dose
CRVO sits 46% above its 52-week low of $2.13 on light trading volume (0.2× avg).
Summary
At AAIC 2026, CervoMed presented new Phase 2b analyses showing neflamapimod's treatment effect in pure DLB, durable slowing of brain atrophy, and a safe 80 mg BID dose — all supporting a planned Phase 3 trial and partnership discussions.
Key Events · Product Development and Regulatory · CRVO
-
Phase 2b Data Reinforce Pure DLB Effect
New analyses from the 159-patient RewinD-LB trial show neflamapimod slowed worsening of DLB in patients with low plasma pTau181 (<21 pg/mL) and adequate drug exposure, supporting the planned Phase 3 population and 50 mg TID dose.
-
Basal Forebrain Atrophy Slowed
Over 48 weeks, neflamapimod-treated participants showed increased right basal forebrain volume and functional connectivity relative to placebo, targeting the primary pathogenic driver of DLB.
-
80 mg BID Dose Safe and Active
A separate Phase 2 study met primary safety, tolerability, and PK objectives, with secondary findings of stabilized executive function and global cognition in 26 DLB patients.
-
Phase 3 Path De-Risked
The data strengthen the scientific rationale for the planned Phase 3 trial, for which CervoMed has alignment with FDA and EU regulators, and support ongoing strategic partnership discussions.
Analysis · CRVO · Life Sciences
At AAIC 2026, CervoMed revealed new analyses from its Phase 2b RewinD-LB trial that reinforce neflamapimod's treatment effect in 'pure' DLB patients without Alzheimer's co-pathology and support the 50 mg TID dose for a planned Phase 3 study. The data also show durable slowing of basal forebrain atrophy and increased connectivity, plus a separate Phase 2 study where an 80 mg BID dose met safety and PK goals with encouraging clinical activity. This is the first detailed look at the biomarker and imaging evidence backing the company's registration path, coming just weeks after a $10.5M private placement and a $10M registered direct offering that extended cash runway into Q2 2027. The positive data de-risks the Phase 3 program and strengthens the case for a strategic partnership, which management has stated is the focus for advancing neflamapimod.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRVO was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.7M. The 52-week trading range was $2.13 to $13.13. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.